CA$140-175k
+ Stock Option Grants
AI-powered intelligence for pharma commerical teams
Open for applications
AI-powered intelligence for pharma commerical teams
101-200 employees
Open for applications
CA$140-175k
+ Stock Option Grants
101-200 employees
To reduce patients time to therapy by enabling meaningful interactions with healthcare providers, powered by AI-driven, human-centric software.
Jump to section
To reduce patients time to therapy by enabling meaningful interactions with healthcare providers, powered by AI-driven, human-centric software.
49% employee growth in 12 months
ODAIA have been growing fast in recent years. The company began in the University of Toronto with an intensive period of R&D in AI, journey mapping, and process mining. From there, the ODAIA commercial insights platform for the pharmaceuticals industry was born. Its MAPTUAL solution uses AI and predictive analytics on a vast spread of data to segment and target physicians, thereby driving up customer engagement.
Its rapid growth can be put down, in part, to a widespread shift in the way healthcare providers (HCPs) interact with Pharma, precipitated by the COVID pandemic. With on-site visits restricted, pharma reps needed to seek out different ways of forging meaningful client connections. What we’re seeing now is pharma messaging developing into more detailed, tailored forms of HCP support. As we’ve seen with marketing more generally, big data analytics is a phenomenally powerful tool for maintaining this competitive, tailored edge and funding awarded in 2023 proves that ODAIA's AI is being tipped as a solution for the "bottleneck" in pharma delivery and testing.
This means that ODAIA is blazing what is likely to prove an impressive trail in the new model of Pharma/HCP relations. Offering a more streamlined, modern method of targeting and value production, ODAIA is likely to prove an increasingly crucial player going forward in a highly lucrative market.

Steph
Company Specialist at Welcome to the Jungle
May 2023
$25m
SERIES B
Feb 2022
$13.8m
SERIES A
This company has top investors
Philip Poulidis
(Co-Founder & CEO)Veteran public company executive leader, board member, and startup CEO with experience in the IoT, Semiconductor, Digital Health, and Enterprise SaaS markets.
Software Engineering
Marketing
Product